Literature DB >> 20233590

Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.

Scott W Blume1, Nateka L Jackson, Andra R Frost, William E Grizzle, Oleg D Shcherbakov, Hyoungsoo Choi, Zheng Meng.   

Abstract

Genes involved in the control of cell proliferation and survival (those genes most important to cancer pathogenesis) are often specifically regulated at the translational level, through RNA-protein interactions involving the 5'-untranslated region of the mRNA. IGF1R is a proto-oncogene strongly implicated in human breast cancer, promoting survival and proliferation of tumor cells, as well as metastasis and chemoresistance. Our lab has focused on the molecular mechanisms regulating IGF1R expression at the translational level. We previously discovered an internal ribosome entry site (IRES) within the 5'-untranslated region of the human IGF1R mRNA, and identified and functionally characterized two individual RNA-binding proteins, HuR and hnRNP C, which bind the IGF1R 5'-UTR and differentially regulate IRES activity. Here we have developed and implemented a high-resolution northwestern profiling strategy to characterize, as a group, the full spectrum of sequence-specific RNA-binding proteins potentially regulating IGF1R translational efficiency through interaction with the 5'-untranslated sequence. The putative IGF1R IRES trans-activating factors (ITAFs) are a heterogeneous group of RNA-binding proteins including hnRNPs originating in the nucleus as well as factors tightly associated with ribosomes in the cytoplasm. The IGF1R ITAFs can be categorized into three distinct groups: (a) high molecular weight external ITAFs, which likely modulate the overall conformation of the 5'-untranslated region of the IGF1R mRNA and thereby the accessibility of the core functional IRES; (b) low molecular weight external ITAFs, which may function as general chaperones to unwind the RNA, and (c) internal ITAFs which may directly facilitate or inhibit the fundamental process of ribosome recruitment to the IRES. We observe dramatic changes in the northwestern profile of non-malignant breast cells downregulating IGF1R expression in association with acinar differentiation in 3-D culture. Most importantly, we are able to assess the RNA-binding activities of these putative translation-regulatory proteins in primary human breast surgical specimens, and begin to discern positive correlations between individual ITAFs and the malignant phenotype. Together with our previous findings, these new data provide further evidence that pathological dysregulation of IGF1R translational control may contribute to development and progression of human breast cancer, and breast metastasis in particular. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233590      PMCID: PMC2868104          DOI: 10.1016/j.yexmp.2010.03.006

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  50 in total

1.  A cell cycle-dependent protein serves as a template-specific translation initiation factor.

Authors:  E V Pilipenko; T V Pestova; V G Kolupaeva; E V Khitrina; A N Poperechnaya; V I Agol; C U Hellen
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

2.  The human IGF1R IRES likely operates through a Shine-Dalgarno-like interaction with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by a naturally polymorphic polyU loop.

Authors:  Zheng Meng; Nateka L Jackson; Oleg D Shcherbakov; Hyoungsoo Choi; Scott W Blume
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

3.  Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects.

Authors:  J L Gooch; C L Van Den Berg; D Yee
Journal:  Breast Cancer Res Treat       Date:  1999-07       Impact factor: 4.872

4.  The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Authors:  Raushan T Kurmasheva; Lorina Dudkin; Catherine Billups; Larisa V Debelenko; Christopher L Morton; Peter J Houghton
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

5.  Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.

Authors:  Xianke Zeng; Deepali Sachdev; Hua Zhang; Martine Gaillard-Kelly; Douglas Yee
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 6.  Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.

Authors:  Brent N Rexer; Jeffrey A Engelman; Carlos L Arteaga
Journal:  Cell Cycle       Date:  2009-01-30       Impact factor: 4.534

7.  Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.

Authors:  Todd W Miller; Marianela Pérez-Torres; Archana Narasanna; Marta Guix; Olle Stål; Gizeh Pérez-Tenorio; Ana M Gonzalez-Angulo; Bryan T Hennessy; Gordon B Mills; J Phillip Kennedy; Craig W Lindsley; Carlos L Arteaga
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

8.  Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

Authors:  John S P Yuen; Erdem Akkaya; Yong Wang; Megumi Takiguchi; Sandra Peak; Mark Sullivan; Andrew S Protheroe; Valentine M Macaulay
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

Review 9.  Mammary field cancerization: molecular evidence and clinical importance.

Authors:  Christopher M Heaphy; Jeffrey K Griffith; Marco Bisoffi
Journal:  Breast Cancer Res Treat       Date:  2009-08-15       Impact factor: 4.872

10.  The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.

Authors:  D Sachdev; X Zhang; I Matise; M Gaillard-Kelly; D Yee
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

View more
  5 in total

1.  HNRNPC as a candidate biomarker for chemoresistance in gastric cancer.

Authors:  Hao Huang; Yong Han; Cheng Zhang; Jian Wu; Junnan Feng; Like Qu; Chengchao Shou
Journal:  Tumour Biol       Date:  2015-10-09

2.  Silence of S1 RNA binding domain 1 represses cell growth and promotes apoptosis in human non-small cell lung cancer cells.

Authors:  Tao Zhang; Guowei Cheng; Lei Deng; Yin Yang; Li Sun; Ping Chen; Xiangling He; Dan Su; Nan Bi; Bin Qiu
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Small molecule inhibitors of IRES-mediated translation.

Authors:  Christos Vaklavas; Zheng Meng; Hyoungsoo Choi; William E Grizzle; Kurt R Zinn; Scott W Blume
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

4.  Overexpression of hnRNPC2 induces multinucleation by repression of Aurora B in hepatocellular carcinoma cells.

Authors:  DA-Quan Sun; Ying Wang; Ding-Gan Liu
Journal:  Oncol Lett       Date:  2013-01-31       Impact factor: 2.967

5.  IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells.

Authors:  Christos Vaklavas; William E Grizzle; Hyoungsoo Choi; Zheng Meng; Kurt R Zinn; Kedar Shrestha; Scott W Blume
Journal:  Tumour Biol       Date:  2016-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.